Skip to main content

Table 3 Linear mixed models of Despair, Impaired Ambulation, and Impaired Performance

From: Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States

 DespairaImpaired AmbulationbImpaired Performancec
EffectEstimate (SE)P-valueEstimate (SE)P-valueEstimate (SE)P-value
Intercept61.22 (9.271)< 0.000152.86 (8.981)< 0.000141.96 (9.271)0.0001
Time (months) since diagnosis− 0.15 (0.048)0.003− 0.03 (0.026)0.256− 0.04 (0.037)0.241
Treatment: cetuximab±RT (vs. cisplatin±RT)6.62 (2.010)0.001−0.82 (1.570)0.602−0.13 (1.703)0.941
Treatment* time since diagnosis−0.21 (0.141)0.1290.08 (0.092)0.390−0.01 (0.140)0.930
Age at diagnosis−0.27 (0.084)0.001−0.08 (0.065)0.249−0.05 (0.067)0.477
Male (vs. female)−1.32 (1.702)0.438− 1.63 (1.204)0.175−0.45 (1.227)0.713
White (vs. minority/unknown)2.91 (1.513)0.055−0.40 (1.114)0.7201.62 (1.133)0.152
Impaired composite performance status (vs. not impaired)−0.62 (2.846)0.8293.34 (2.146)0.1202.30 (2.193)0.294
Weighted index of comorbid conditions0.35 (0.875)0.6891.33 (0.570)0.0200.77 (0.583)0.189
Smoking status: current or past (vs. never/unknown/undocumented)1.90 (1.910)0.3211.67 (1.398)0.2312.36 (1.429)0.100
Alcohol status0.4240.3070.357
 Current or past abuse (vs. never/unknown/undocumented)−0.82 (1.984)0.6791.01 (1.460)0.4900.66 (1.491)0.660
 Current or past use (vs. never/unknown/undocumented)−2.09 (1.633)0.201−0.91 (1.184)0.445−1.08 (1.209)0.370
Stage at start: Stage III (vs. Stage IV)0.53 (1.377)0.698−0.60 (1.058)0.571−0.02 (1.076)0.989
Oral (vs. non-oral)−4.92 (3.910)0.209−0.84 (2.822)0.766−0.48 (2.892)0.869
Pharynx (vs. non-pharynx)−5.00 (3.557)0.161−0.61 (2.788)0.826−0.92 (2.851)0.746
Larynx (vs. non-larynx)−4.30 (3.702)0.246−3.84 (2.959)0.195−3.27 (3.022)0.279
HPV test results (positive vs. non-positive)−6.18 (4.057)0.1280.715 (3.091)0.8170.62 (3.177)0.845
P16 test results (positive vs. non-positive)0.69 (1.976)0.7281.528 (1.194)0.2011.46 (1.218)0.231
Feeding tube placement (vs. not placed)0.060 (1.451)0.9670.54 (1.076)0.6131.20 (1.097)0.273
BMI0.055 (0.109)0.6120.08 (0.086)0.3760.12 (0.087)0.155
Insurance0.0140.0080.001
 Only public (vs. only private)4.57 (1.956)0.0204.65 (1.424)0.0015.70 (1.452)< 0.0001
 Both public and private (vs. only private)5.53 (1.793)0.0023.20 (1.338)0.0173.77 (1.365)0.006
 Other/unknown/undocumented (vs. only private)1.72 (4.638)0.7113.66 (3.308)0.2685.54 (3.403)0.104
US region South (vs. non-South)3.20 (5.737)0.5771.69 (6.750)0.802−1.57 (7.014)0.823
  1. Reference level for each comparison is in parentheses
  2. BMI body mass index, HPV human papilloma virus, RT radiation therapy, SE standard error, US United States
  3. aAnalysis is based on 163 patients and 1048 observations
  4. bAnalysis is based on 218 patients and 1320 observations
  5. cAnalysis is based on 218 patients and 1311 observations
  6. *refers to an interaction